AGP Executive Report

Drug Approvals: The FDA approved oral pritelivir for hard-to-treat herpes simplex lesions in immunocompromised adults, offering a new option for infections that can be difficult to manage with existing antivirals. The agency also approved a once-monthly olanzapine injection for adults with schizophrenia. Cancer Care: Tecentriq won approval with chemotherapy as adjuvant treatment for stage III dMMR colon cancer. Diagnostic Equity: VisualDx CEO Art Papier says gaps in medical training on skin of color still contribute to missed diagnoses, especially in primary care and emergency settings. Drug Pricing: Pharmaceutical companies are challenging the Trump administration’s most-favored-nation drug-pricing policy in court.

Cancer Costs: India will cap trade margins on non-scheduled cancer drugs at 30%; medical-device makers are seeking similar controls, while experts say any cuts must reach patients without disrupting supply or quality. Maternal Care: Uttar Pradesh is expanding single-dose iron injections for pregnant women after a five-district pilot, aiming to improve treatment access and address anemia-related risks. Treatment Advances: The FDA approved once-monthly olanzapine for adults with schizophrenia and Tecentriq with chemotherapy for stage III dMMR colon cancer. Separately, early data on investigational CAR T therapy prula-cel showed remission in some patients with lupus, but the Phase 1 results involve a small group and need further study. Industry Influence: A new analysis links pharmaceutical company payments to changes in physicians’ prescribing, adding to calls for stronger scrutiny of drug marketing. Healthcare Costs: California’s plan to fine hospitals that exceed spending targets faces industry opposition, with critics arguing the caps may not account for inflation, drug costs, and an aging population.

Drug Approvals: The FDA approved Teva’s once-monthly injectable olanzapine for adults with schizophrenia. Unlike an older injectable version, it requires no loading dose, oral add-on or post-injection monitoring. Roche’s Tecentriq plus chemotherapy also won approval for stage III dMMR colon cancer, after trial data showed a 50% lower risk of recurrence or death. Measles Outbreak: U.S. cases topped 4,080, including 1,136 in Pennsylvania, where five people have died. Nationwide, 95% of cases were in people who were unvaccinated or whose status was unknown. Hospital Finances: The American Hospital Association and Maine hospitals sued to block a planned 340B drug rebate program, warning it could add more than $1 billion in annual administrative costs. Medicare & Rural Care: CMS released 2027 Medicare Advantage star ratings ahead of open enrollment; about 71% of enrollees are in plans rated four stars or higher. The agency also issued its first report on states’ use of a $50 billion rural health fund. Cybersecurity: U.S. and international agencies warned that China-linked hackers are targeting critical infrastructure, including healthcare organizations, to steal sensitive data.

Drug Pricing: India has capped trade margins on non-scheduled cancer medicines at 30% of retail price, a move expected to cut some prices by up to 70%. The Supreme Court also told the government to form a panel on pharmaceutical freebies to doctors and unethical marketing. Prescribing Practices: A Cochrane review of more than 93 studies found that industry payments, gifts and sales visits are linked to doctors prescribing promoted drugs more often, including potentially inappropriate treatments. New Treatments: The FDA granted fast track status to VIR-5500, an experimental therapy for advanced prostate cancer. A trial of a daily GLP-1 pill for type 2 diabetes reported HbA1c reductions of up to 1.6%. Care and Coverage: Doctors and radiologists are pushing back against a proposed change to the No Surprises Act, warning that replacing independent payment arbitration with median in-network rates could weaken safeguards against low insurer payments. Clinical Guidance: New UTI guidelines emphasize infection severity when choosing initial antibiotics, while noting that local resistance data may not reflect risk for every patient.

Cancer Care: The FDA approved atezolizumab with chemotherapy for stage III dMMR colon cancer. In multiple myeloma, the iberdomide triplet more than doubled median progression-free survival versus standard therapy in a phase 3 trial. New Treatment Options: The FDA also cleared remibrutinib for symptomatic dermographism and approved a Tukysa combination as maintenance therapy for HER2-positive metastatic breast cancer. Heart Failure: An FDA-cleared CardioMEMS update lets patients view pressure readings on their phones. Prescribing Oversight: A Cochrane review found pharma gifts and payments were linked to more inappropriate and costly prescribing. India’s Supreme Court ordered a panel to recommend rules on industry freebies to doctors. Drug Pricing: PhRMA sued to block Medicare’s GLOBE model, which would tie rebates for some Part B drugs to prices in 19 countries.

Ebola Alert: Kenya confirmed its first imported Bundibugyo case, prompting contact tracing and quarantines as officials respond to the deadly outbreak. Cancer Care: The FDA approved Tukysa with trastuzumab and pertuzumab as first-line maintenance treatment for HER2-positive metastatic breast cancer. India capped trade margins on non-scheduled cancer drugs at 30%, which could cut some prices by up to 70%; the Supreme Court also ordered a panel to recommend safeguards against drug-company gifts to doctors. Heart Health: GLP-1 therapies featured prominently at the 2026 European cardiology congress, reflecting their expanding role beyond weight and diabetes care. Parkinson’s: Solengepras met its primary endpoint in a Phase 3 trial, reducing daily “off” time compared with placebo. Skin Care: The FDA approved remibrutinib for symptomatic dermographism, a condition that causes itchy skin welts.

Cancer Treatment: The FDA approved Tukysa with trastuzumab and pertuzumab as first-line maintenance therapy for HER2-positive metastatic breast cancer. In a trial, median progression-free survival was 24.9 months, versus 16.3 months with placebo; an overall-survival benefit has not yet been established. Drug Pricing: PhRMA sued to block a Medicare rule linking some Part B drug payments to prices abroad, arguing the administration lacks authority to impose the policy. Infectious Disease: Kenya reported its first case in the current Ebola outbreak after a man arriving from the Democratic Republic of Congo died in Nairobi. Ten people are quarantined as officials trace 57 contacts. Biotech: Caribou Biosciences is ending two CAR-T programs and weighing strategic options, citing a difficult funding environment. Manufacturing: Thermo Fisher is expanding sterile-drug production in the US and Italy, including capacity for vials, prefilled syringes and monoclonal antibodies.

Vaccine Progress: Vaxcyte says its Phase 3 VAX-31 pneumococcal vaccine met primary endpoints, with immune responses across 31 strains and a safety profile similar to existing vaccines. Drug Development: CSL and Alentis struck a deal worth up to $1.55 billion to develop a kidney and liver disease drug; Genentech licensed Alector’s experimental Parkinson’s therapy in a deal worth up to $1.27 billion. Market Access: Celltrion has launched Omlyclo in the US, the first interchangeable biosimilar to Xolair. Infectious Disease: Florida reported 252 locally acquired dengue cases by late September, far above recent years. India is also launching youth-led TB awareness teams in 55 districts, alongside an AI-powered public information chatbot. Earlier Intervention: Experts are urging primary care to play a larger role in liver disease as cases linked to obesity and alcohol rise.

Healthcare Costs & Access: A new Urban Institute survey finds medical debt hits more than 1 in 4 U.S. adults, with hospital bills the biggest driver and gaps in insurance coverage worsening the problem. Medication Use Disparities: Diabetes drug adherence lags for Black and Hispanic Medicare patients, with plan design and coverage levels linked to smaller or larger gaps. Pharmacy Pricing Reality Check: Cost-plus pricing is reshaping pharmacy expectations, but reported savings aren’t guaranteed for every patient. FTC Price-Transparency Push: The FTC sent warning letters to 24 healthcare organizations over alleged failures to provide timely, accurate pricing. Practice Operations: MGMA centennial sessions highlighted how practices can recover revenue, negotiate with payers, and use a simple 15-minute morning huddle to reduce staff strain. Cybersecurity for Hospitals: Experts warn leaders to plan for prolonged tech outages and AI-driven cyber threats, not just classic disaster recovery. Cancer & Drug Updates: FDA approvals and late-stage trial readouts span breast cancer, DLBCL, prostate cancer immunotherapy, and smoldering myeloma, with several studies emphasizing deeper response and longer follow-up. AI in Care Delivery: Utah approved more healthcare AI pilots, including acne prescribing with delayed clinician review. Public Health & Safety: Poison Control is warning families about the “Benadryl Challenge” after a New Jersey teen was hospitalized.

GLP-1 Shift to Oral Options: The oral GLP-1 market is projected to surge as Novo and others push easier-to-take formulations, with industry focus expanding beyond weight loss into broader chronic disease benefits. Drug Delivery Innovation: Lexaria’s DehydraTECH is being evaluated to improve oral absorption and reduce side effects, while a separate patent filing targets a new biologics platform built for scalable manufacturing. Clinical Trials & Data: Oku Digital Health launched an ocular-data network to speed trial recruitment and generate real-world evidence, and coverage highlights how connecting real-world data to the patient journey still runs into interoperability and workflow barriers. FDA/Trials Oversight: The FDA is seeking public input on early-phase ibogaine trial design, while ACT Briefs flag gaps in outsourcing oversight as mixed models spread. Cancer Care Updates: Ernexa Therapeutics’ ERNA-101 was selected for a Nature/MD Anderson flash talk, and Regeneron shared new ESMO 2026 research spanning multiple cancers and cancer-associated thrombosis. Pricing Transparency Rules: CMS announced new regulations to make healthcare pricing and coverage info easier to find, compare, and report. Policy & Access: Utah launched AI pilots for healthcare processes, and India’s eSanjeevani hit 50 crore teleconsultations, with women driving over half of visits.

Healthcare Pricing & PBMs: A new look at how cost-plus formulas and rebate math can distort drug and pharmacy benefit decisions highlights why “a formula is not a guarantee,” with PBMs shifting toward more cost-based reimbursement while pharmacists translate complexity into patient care. Hospital Value-Chain Scrutiny: Max Healthcare’s chairman argues hospital pricing should be judged across the full care value chain—not just individual items—amid legal and regulatory pressure over steep markups. Biosimilars Under Pressure: An interview explains why rebate structures and formulary control can keep biosimilars from gaining ground, even when clinical differences are modest. Community CAR-T Scaling: Reimagine Care discusses how remote monitoring plus AI triage aims to help community practices scale CAR-T programs without ballooning staffing. AI in Revenue Cycle: AKASA launches “autonomous” mid-cycle coding to fully code inpatient cases in about 90 seconds after discharge. Diabetes Supply Update: Novo Nordisk plans to withdraw Levemir insulin in all forms by end of 2026, with guidance for switching to alternatives. Oncology Pipeline Highlights: Multiple trial updates span oral SERDs, myeloma triplet comparisons, and RAS G12D PDAC combination studies, alongside early results for localized cisplatin patches in oral cancer. Aged Care Leadership: Aged Care Decisions appoints a new CEO as it continues helping families navigate placement options. Workforce & Wellness: India’s Ayush services sector is reported to support 1.76M livelihoods, with women making up 43% of the workforce.

Military Health & Accountability: U.S. soldiers wounded in an Iranian drone strike in Kuwait say commanders underestimated the threat and that the military medical system failed them, with the Pentagon releasing few details. Public Health Threats: Russia is investigating a suspected pneumonic plague death of a lab worker in Siberia; authorities report nearly 200 close contacts under observation as EU and global health agencies watch closely. Healthcare Access & Safety: A Boston-bound medical flight from Bermuda vanished over the Atlantic; six people are presumed dead, raising questions about emergency transport safety. Responsible AI in Care: Autonomize AI joined NCQA’s AI Learning Collaborative focused on responsible use of AI for prior authorization, emphasizing governance and measurable impact. Pharma & Biotech Moves: Gland Pharma approved a $21M U.S. expansion to acquire a 60% stake in Novelstar Pharma; ARC Regulatory secured £3.7M in new lab projects with global pharma. Clinical & Treatment Updates: FDA cleared an AI tool for pediatric bone age assessments; Cordis’ SELUTION SLR drug-eluting balloon won U.S. approval for in-stent restenosis. Cancer Care Data: Experts discussed reducing false positives on prostate PSMA PET and better handling indeterminate bone lesions in imaging.

Pharma & Markets: Eli Lilly’s diabetes/obesity engine is still widening its moat, with Mounjaro and Zepbound driving most revenue growth and strong patent protection through the 2030s and beyond. Cancer Screening & Regulation: The FDA advisory panel backed GRAIL’s Galleri multi-cancer blood test, setting up a potential approval decision in the coming months. AI in Drug Discovery: At an Abu Dhabi AI event, Insilico Medicine highlighted how AI is accelerating target finding and molecule design, with some candidates moving into late-stage trials. Breast Cancer Prevention Gap: A new American Cancer Society survey finds awareness of modifiable breast cancer risk factors is high, but many women aren’t translating it into action. UTI Guidance Update: Multiple urology and infectious disease groups released recent guideline updates for urinary tract infections. Oncology Care Delivery: MUSC is piloting virtual nurse intake in ED arrival workflows to speed triage and reduce crowding. Manufacturing Capacity: Bayer plans a $2.2B Ohio manufacturing campus to expand drug substance and product output for oncology, cardiovascular, and renal care. Clinical Trial Watch: Phase 3 PROPEL is testing subcutaneous imeroprubart for generalized myasthenia gravis, with results expected to clarify dosing and patient outcomes.

Wearables & IPO Mood: Oura’s smart-ring IPO was postponed after being reported as heavily oversubscribed, underscoring how fast public-market sentiment can swing for health tech. AI for Chronic Disease: A former OpenAI exec is using AI to tackle chronic conditions, including her own POTS, via a new biotech effort. Mental Health Care Delivery: At a psychiatry conference, experts argued long-acting injectable antipsychotics can improve relapse prevention and make nonadherence visible, while AI decision tools must avoid “hallucinations” by asking missing questions first. Dementia Diagnostics: Clinicians highlighted blood-based Alzheimer biomarkers as a way to close diagnostic gaps and move beyond vague “dementia” labels. Women’s Health Access: In Idaho, abortion-rights advocates are reframing the ballot fight around doctor shortages and broader healthcare access, not just the procedure. Regulatory & Public Health Capacity: Nigeria’s NAFDAC urged partners to fund vaccine fill-and-finish manufacturing to reach WHO regulatory maturity. Clinical Care & Devices: Studies reported robotic hip/knee replacement doesn’t clearly cut repeat surgery risk overall, while rectal spacers may reduce proton-therapy toxicity in prostate cancer.

Africa Health Investment Push: Ghana President John Dramani Mahama urged African leaders to treat healthcare as an investable economic sector, calling for more funding for local pharmaceutical manufacturing, regional value chains, and health innovation to cut dependence on imported medicines and vaccines. Cancer Radiotherapy Update: New clinical discussion supports fractionated stereotactic radiosurgery after brain metastasis resection, citing improved surgical-bed control with similar radiation necrosis rates versus single-fraction approaches. Proton Therapy Safety: Research highlights how rectal spacers can reduce rectal dose and potentially lower toxicity during proton therapy for prostate cancer, with patient selection depending on tumor location. Dermatology Real-World Data: EADV reports delgocitinib cream showing real-world effectiveness in chronic hand eczema, plus additional adolescent analyses. Mental Health Care: Conference coverage spotlights covert medication nonadherence in serious mental illness and why anhedonia can signal higher suicide risk. Healthcare Access on the Ground: Niger’s private clinic was re-sealed after failing health standards, including staffing, equipment, and infection prevention gaps.

Obesity Drug Showdown: An indirect comparison links tirzepatide 15 mg to greater weight loss than semaglutide 7.2 mg in SURMOUNT-5, with GI side effects the main discontinuation driver. RSV Prevention Update: Clesrovimab is shown to remain effective and well-tolerated when repeated in infants at risk across a second RSV season. Depression Care Access: New discussion highlights accelerated TMS (SAINT) as a faster path toward remission for treatment-resistant depression, plus MRI-targeting considerations. Dermatology Pipeline: EADV coverage spotlights ritlecitinib repigmentation in nonsegmental vitiligo and deeper-control data across psoriasis/HS/AD programs. Public Health Alerts: Pennsylvania reports a fifth measles death as cases near 1,000; Nepal confirms 131 Japanese encephalitis cases with most unvaccinated. Policy & Competition: AHA backs a hospital challenge to Lilly’s 340B policy, while regulators weigh hospital consolidation and post-acute care differences in Medicare Advantage. Healthcare Ops: Kerala’s health minister denies medicine shortages in government hospitals, blaming pharma and media claims. Genomics for Kids: GeneDx rolls out “Easy Order” to simplify pediatric genomic testing workflows for AAP use.